About Biohaven Pharmaceutical (NYSE:BHVN)
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:BHVN
CUSIPN/A
Phone203-404-0410
Debt
Debt-to-Equity RatioN/A
Current Ratio14.51%
Quick Ratio14.51%
Price-To-Earnings
Trailing P/E Ratio-5.40
Forward P/E Ratio-6.26
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.66 per share
Price / Book7.43
Profitability
EPS (Most Recent Fiscal Year)($5.00)
Net Income$-127,190,000.00
Net MarginsN/A
Return on Equity-86.82%
Return on Assets-76.51%
Miscellaneous
Employees42
Outstanding Shares36,020,000
Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions
What is Biohaven Pharmaceutical's stock symbol?
Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."
How were Biohaven Pharmaceutical's earnings last quarter?
Biohaven Pharmaceutical (NYSE:BHVN) issued its quarterly earnings results on Tuesday, March, 6th. The company reported ($0.75) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.33) by $0.58. View Biohaven Pharmaceutical's Earnings History.
When is Biohaven Pharmaceutical's next earnings date?
What price target have analysts set for BHVN?
6 brokerages have issued 12-month target prices for Biohaven Pharmaceutical's shares. Their forecasts range from $25.00 to $48.00. On average, they expect Biohaven Pharmaceutical's share price to reach $37.8333 in the next year. View Analyst Ratings for Biohaven Pharmaceutical.
What are Wall Street analysts saying about Biohaven Pharmaceutical stock?
Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (4/17/2018)
- 2. Canaccord Genuity analysts commented, "We expect 0.125 and 0.15 mg/kg SVP-Rapamycin data to show robust Serum Uric Acid suppression in severe gout patients when released in April, which should boost SELB shares. We suspect that SELB may present ~n=10-11 patients per cohort, but await final data on the level of pegsiticase dosing, which was 0.2 and 0.4 mg/kg in Phase 2. Importantly, SELB has previously demonstrated that higher doses of SVP-Rapamycin show improving SUA suppression and lower antibody levels, and we would expect 0.125 and 0.15 mg/kg to improve on that trend. As a reminder, SELB showed improving SUA suppression in Phase 1b as SVP-rapamycin doses increased from 0.03 mg/kg to 0.1 mg/kg, and then to 0.15 mg/kg. Patients with SUA levels <6 mg/dL at day 30 were 0%, 70%, and 100% respectively."" (3/7/2018)
- 3. Needham & Company LLC analysts commented, "We recently hosted a series of mtgs w/ Biohaven and investors. Mgmt reiterated guidance for top-line results from both Phase 3 trials of rimegepant in Acute Migraine in 1Q18. We remain positively inclined and believe recent Allergan ubrogepant Phase 3 data set a relatively low bar for rimegepant. The open- label long-term rimegepant Phase 3 trial is half enrolled (1000/ 2000 patients) and mgmt expects to announce results YE18 (unch). Biohaven also disclosed yesterday an exclusive agreement w/ Catalent for development and commercialization of an orally disintegrating tablet (ODT) formulation of a CGRP receptor antagonist. Biohaven plans to initiate a Phase 3 trial of ODT rimegepant in the next few wks to assess potential for a more rapid impact on migraine symptoms. Data will be included in NDA and company plans to launch rimegepant w/ both ODT and tablet formulations. Reiterate BUY." (2/22/2018)
Are investors shorting Biohaven Pharmaceutical?
Biohaven Pharmaceutical saw a increase in short interest in March. As of March 29th, there was short interest totalling 3,038,258 shares, an increase of 97.3% from the March 15th total of 1,539,914 shares. Based on an average daily volume of 2,377,967 shares, the short-interest ratio is presently 1.3 days. Currently, 14.0% of the company's stock are sold short.
Who are some of Biohaven Pharmaceutical's key competitors?
Some companies that are related to Biohaven Pharmaceutical include GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Tesaro (TSRO), Array BioPharma (ARRY), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Ironwood Pharmaceuticals (IRWD), Acadia Pharmaceuticals (ACAD), Clovis Oncology (CLVS) and Supernus Pharmaceuticals (SUPN).
Who are Biohaven Pharmaceutical's key executives?
Biohaven Pharmaceutical's management team includes the folowing people:
- Dr. Vladimir Coric, CEO & Director (Age 47)
- Mr. James Engelhart, CFO & Principal Accounting Officer (Age 54)
- Dr. Robert Berman M.D., Chief Medical Officer and VP (Age 55)
- Dr. Charles Conway Ph.D., Chief Scientific Officer (Age 56)
- Mr. John Tilton, Chief Commercial Officer (Age 50)
When did Biohaven Pharmaceutical IPO?
(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
Has Biohaven Pharmaceutical been receiving favorable news coverage?
News headlines about BHVN stock have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biohaven Pharmaceutical earned a coverage optimism score of 0.13 on Accern's scale. They also gave media headlines about the company an impact score of 46.01 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Biohaven Pharmaceutical?
Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biohaven Pharmaceutical's stock price today?
One share of BHVN stock can currently be purchased for approximately $27.19.
How big of a company is Biohaven Pharmaceutical?
Biohaven Pharmaceutical has a market capitalization of $951.94 million. The company earns $-127,190,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Biohaven Pharmaceutical employs 42 workers across the globe.
How can I contact Biohaven Pharmaceutical?
Biohaven Pharmaceutical's mailing address is 234 CHURCH STREET SUITE 304, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.
MarketBeat Community Rating for Biohaven Pharmaceutical (BHVN)
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biohaven Pharmaceutical (NYSE:BHVN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Biohaven Pharmaceutical in the last 12 months. Their average twelve-month price target is $37.8333, suggesting that the stock has a possible upside of 39.14%. The high price target for BHVN is $48.00 and the low price target for BHVN is $25.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $37.8333 | $38.6667 | $38.00 | $40.80 |
| Price Target Upside: | 39.14% upside | 68.41% upside | 73.28% upside | 14.74% upside |
Biohaven Pharmaceutical (NYSE:BHVN) Consensus Price Target History
Biohaven Pharmaceutical (NYSE:BHVN) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Biohaven Pharmaceutical (NYSE:BHVN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biohaven Pharmaceutical (NYSE BHVN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 34.20%
Institutional Ownership Percentage: 61.84%
Biohaven Pharmaceutical (NYSE BHVN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/10/2018 | Robert Berman | Insider | Sell | 35,000 | $24.66 | $863,100.00 | |  |
| 3/12/2018 | Robert Berman | Insider | Sell | 35,000 | $30.11 | $1,053,850.00 | | |
| 3/1/2018 | Kimberly Gentile | VP | Sell | 5,000 | $32.87 | $164,350.00 | | |
| 2/21/2018 | James Engelhart | CFO | Sell | 538 | $29.60 | $15,924.80 | 3,038 | |
| 2/12/2018 | Robert Berman | Insider | Sell | 35,000 | $30.42 | $1,064,700.00 | | |
| 2/1/2018 | Kimberly Gentile | VP | Sell | 5,000 | $32.78 | $163,900.00 | 5,000 | |
| 1/31/2018 | Gregory Bailey | Director | Sell | 50,000 | $33.71 | $1,685,500.00 | 2,516,701 | |
| 1/22/2018 | Gregory Bailey | Director | Sell | 49,000 | $30.76 | $1,507,240.00 | 2,583,289 | |
| 1/22/2018 | James Engelhart | CFO | Sell | 10,000 | $32.50 | $325,000.00 | 13,576 | |
| 1/19/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 35,119 | $30.03 | $1,054,623.57 | | |
| 1/18/2018 | Declan Doogan | Director | Sell | 128,058 | $26.95 | $3,451,163.10 | 2,583,289 | |
| 1/16/2018 | Gregory Bailey | Director | Sell | 40,000 | $26.52 | $1,060,800.00 | | |
| 1/12/2018 | Declan Doogan | Director | Sell | 121,942 | $26.78 | $3,265,606.76 | | |
| 1/10/2018 | Declan Doogan | Director | Sell | 40,362 | $27.69 | $1,117,623.78 | | |
| 1/10/2018 | Robert Berman | Insider | Sell | 35,000 | $27.52 | $963,200.00 | | |
| 1/9/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 84,881 | $30.06 | $2,551,522.86 | 6,278,504 | |
| 1/5/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 22,996 | $30.03 | $690,569.88 | 6,278,504 | |
| 1/4/2018 | Gregory Bailey | Director | Sell | 50,000 | $28.71 | $1,435,500.00 | 1,187,275 | |
| 1/3/2018 | Portage Biotech Inc. | Major Shareholder | Sell | 35,650 | $28.61 | $1,019,946.50 | 124,371 | |
| 1/2/2018 | Kimberly Gentile | VP | Sell | 5,000 | $27.60 | $138,000.00 | 5,000 | |
| 12/20/2017 | Gregory Bailey | Director | Sell | 39,430 | $26.31 | $1,037,403.30 | 1,234,077 | |
| 12/19/2017 | Robert Berman | Insider | Sell | 10,000 | $24.10 | $241,000.00 | | |
| 12/11/2017 | Robert Berman | Insider | Sell | 25,000 | $21.28 | $532,000.00 | | |
| 12/1/2017 | Kimberly Gentile | VP | Sell | 5,000 | $21.99 | $109,950.00 | | |
| 11/30/2017 | Gregory Bailey | Director | Sell | 9,970 | $25.48 | $254,035.60 | 1,262,759 | |
| 11/27/2017 | Gregory Bailey | Director | Sell | 20,600 | $25.92 | $533,952.00 | 1,289,699 | |
| 11/24/2017 | Gregory Bailey | Director | Sell | 600 | $26.02 | $15,612.00 | 1,289,699 | |
| 11/14/2017 | Robert Berman | Insider | Sell | 160,000 | $25.76 | $4,121,600.00 | | |
| 11/10/2017 | James Engelhart | CFO | Sell | 30,538 | $26.58 | $811,700.04 | 25,176 | |
| 11/9/2017 | Robert Berman | Insider | Sell | 27,423 | $26.60 | $729,451.80 | | |
| 11/1/2017 | John Tilton | Insider | Sell | 30,000 | $29.25 | $877,500.00 | 30,000 | |
| 11/1/2017 | Kimberly Gentile | VP | Sell | 5,000 | $29.28 | $146,400.00 | 5,000 | |
| 11/1/2017 | Vlad Coric | CEO | Sell | 150,000 | $29.41 | $4,411,500.00 | | |
| 5/9/2017 | Albert Cha | Director | Buy | 470,000 | $17.00 | $7,990,000.00 | | |
| 5/9/2017 | James Engelhart | CFO | Buy | 2,500 | $17.00 | $42,500.00 | 3,576 | |
| 5/9/2017 | Robert Berman | Insider | Buy | 50 | $17.00 | $850.00 | | |
(Data available from 1/1/2013 forward)
Biohaven Pharmaceutical (NYSE BHVN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | FY2020 Earnings Estimate for Biohaven Pharmaceutical (BHVN) Issued By William Blair
www.americanbankingnews.com - April 26 at 11:28 AM |
 | Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant
seekingalpha.com - April 23 at 8:58 AM |
 | Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine
finance.yahoo.com - April 23 at 8:58 AM |
| Biohaven Pharmaceutical (BHVN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 23 at 3:34 AM |
 | An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR.)
www.finanznachrichten.de - April 21 at 9:05 AM |
 | Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles
www.prnewswire.com - April 19 at 3:48 AM |
 | Commit To Purchase Biohaven Pharmaceutical Holding At $17.50, Earn 6.8% Annualized Using Options
www.nasdaq.com - April 18 at 4:55 PM |
| Biohaven Pharmaceutical (BHVN) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 7:34 PM |
| Short Interest in Biohaven Pharmaceutical (BHVN) Increases By 97.3%
www.americanbankingnews.com - April 17 at 1:37 AM |
| -$0.87 Earnings Per Share Expected for Biohaven Pharmaceutical (BHVN) This Quarter
www.americanbankingnews.com - April 15 at 11:15 AM |
| Insider Selling: Biohaven Pharmaceutical (BHVN) Insider Sells 35,000 Shares of Stock
www.americanbankingnews.com - April 12 at 7:17 PM |
| Biohaven Pharmaceutical (BHVN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 10 at 12:03 AM |
| Biohaven Pharmaceutical (BHVN) PT Lowered to $36.00 at Needham & Company LLC
www.americanbankingnews.com - April 8 at 8:05 AM |
| Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference
finance.yahoo.com - April 5 at 4:37 PM |
| Biohaven Pharmaceutical (BHVN) Downgraded by Barclays to Equal Weight
www.americanbankingnews.com - April 5 at 11:32 AM |
| Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
finance.yahoo.com - April 3 at 9:30 AM |
| Biohaven Pharmaceutical (BHVN) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:39 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 29 at 3:25 AM |
 | Canaccord Sees An 'Intriguing Setup' In Biohaven Following Reaction To Phase 3 News
www.msn.com - March 28 at 9:29 AM |
| Biohaven Pharmaceutical Target of Unusually High Options Trading (BHVN)
www.americanbankingnews.com - March 28 at 7:40 AM |
| Stock Traders Buy Large Volume of Biohaven Pharmaceutical Put Options (BHVN)
www.americanbankingnews.com - March 28 at 6:45 AM |
| Biohaven Pharmaceutical (BHVN) Rimegepant Pivotal Phase 3 Trial Results - Slideshow
seekingalpha.com - March 27 at 4:33 PM |
| Biohaven Pharmaceutical (BHVN) Earns "Buy" Rating from Piper Jaffray
www.americanbankingnews.com - March 27 at 9:43 AM |
| Here’s What’s Moving AnaptysBio and Biohaven Pharmaceutical
finance.yahoo.com - March 27 at 9:37 AM |
| Biohaven Pharmaceutical (BHVN) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - March 26 at 9:18 PM |
| Here's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today
finance.yahoo.com - March 26 at 4:32 PM |
 | Biohaven (BHVN) Reports Positive Top-Line Results from Phase 3 Clinical Trials (BHV3000-301 & BHV3000-302) of Rimegepant
www.streetinsider.com - March 26 at 9:37 AM |
| Positive late-stage results for Biohaven's rimegepant fails to lift shares, down 29% premarket
seekingalpha.com - March 26 at 9:37 AM |
| Biohaven shares drop 23% after migraine drug trial results
finance.yahoo.com - March 26 at 9:37 AM |
| Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN): Is Breakeven Near?
finance.yahoo.com - March 21 at 10:17 AM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 35,000 Shares
www.americanbankingnews.com - March 14 at 7:12 PM |
| Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options
finance.yahoo.com - March 13 at 6:31 PM |
| -$0.87 EPS Expected for Biohaven Pharmaceutical Holding Co Ltd (BHVN) This Quarter
www.americanbankingnews.com - March 12 at 11:22 AM |
| Biohaven Pharmaceutical (BHVN) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - March 9 at 6:49 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Expected to Earn Q1 2018 Earnings of ($0.69) Per Share
www.americanbankingnews.com - March 9 at 8:04 AM |
| Brokers Issue Forecasts for Biohaven Pharmaceutical Holding Co Ltd's Q2 2018 Earnings (BHVN)
www.americanbankingnews.com - March 8 at 8:20 AM |
| Stock Traders Buy Large Volume of Call Options on Biohaven Pharmaceutical (BHVN)
www.americanbankingnews.com - March 8 at 8:14 AM |
| Biohaven Pharmaceutical Target of Unusually Large Options Trading (BHVN)
www.americanbankingnews.com - March 8 at 8:14 AM |
| Canaccord Genuity Reaffirms Buy Rating for Biohaven Pharmaceutical (BHVN)
www.americanbankingnews.com - March 7 at 8:34 PM |
| Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial And Business Results
finance.yahoo.com - March 6 at 4:58 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Shares Bought by VHCP Management II LLC
www.americanbankingnews.com - March 6 at 11:01 AM |
 | BRIEF-Biohaven Says Expects Topline Results From Phase 3 Trial With Rimegepant Zydis ODT In Q4
www.reuters.com - March 6 at 9:06 AM |
| Kimberly Gentile Sells 5,000 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock
www.americanbankingnews.com - March 5 at 7:16 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Shares Bought by Emory University
www.americanbankingnews.com - March 4 at 2:59 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 4 at 3:30 AM |
| Carillon Tower Advisers Inc. Takes $18.63 Million Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)
www.americanbankingnews.com - March 1 at 5:38 AM |
| American Century Companies Inc. Acquires 20,444 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN)
www.americanbankingnews.com - February 28 at 4:18 AM |
| Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) CFO Sells 538 Shares of Stock
www.americanbankingnews.com - February 23 at 7:08 PM |
| Biohaven Pharmaceutical Holding Co Ltd (BHVN) Expected to Post Earnings of -$1.33 Per Share
www.americanbankingnews.com - February 23 at 11:14 AM |
| Needham & Company LLC Reiterates Buy Rating for Biohaven Pharmaceutical (BHVN)
www.americanbankingnews.com - February 22 at 5:02 PM |
Biohaven Pharmaceutical (NYSE:BHVN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biohaven Pharmaceutical (NYSE:BHVN) Income Statement, Balance Sheet and Cash Flow Statement
Biohaven Pharmaceutical (NYSE BHVN) Stock Chart for Thursday, April, 26, 2018
Loading chart…
